Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoimmune disease.
New T cell-engaging and targeted therapies extend cancer treatment options beyond checkpoint blockers, with expanding clinical evidence.
This Biochemical Pharmacology review synthesizes the evolving landscape of T cell engager and ADC therapies beyond traditional immune checkpoint blockade, covering clinical data across bispecific antibodies and ADCs in oncology and autoimmune disease. Published concurrently with Phase I/II trial data for IMC-C103C (see PMID 42476725), the review provides timely context for the expanding clinical pipeline.
What the study was
- Study design
- Narrative review
- Category
- Other
- Maturity
- Exploratory
- Journal
- Biochem Pharmacol
Why it surfaced
Comprehensive review of T cell engagers and ADCs; Biochem Pharmacol; directly relevant to T6 novel therapeutics watchlist; MEDIUM as review rather than primary data; useful contextual companion to clinical trial data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.